[1]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24-27,32.[doi:10.3969/j.issn.1006-1959.2018.21.008]
　LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(21):24-27,32.[doi:10.3969/j.issn.1006-1959.2018.21.008]
点击复制

中药单体治疗非酒精性脂肪性肝病研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年21期
页码:
24-27,32
栏目:
综述
出版日期:
2018-11-01

文章信息/Info

Title:
Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease
文章编号:
1006-1959（2018）21-0024-05
作者:
李珊珊1; 陈少彬1; 龚先琼2
1.福建中医药大学，福建 福州 351012；2.福建中医药大学附属厦门中医院肝病中心，福建 厦门 361009
Author(s):
LI Shan-shan1; CHEN Shao-bin1; GONG Xian-qiong2
1.Fujian University of Traditional Chinese Medicine,Fuzhou 351012,Fujian,China;2.Liver Disease Center,Xiamen Hospital of Traditional Chinese Medicine,Fujian University of Traditional Chinese Medicine,Xiamen 361009,Fujian,China
关键词:
非酒精性脂肪性肝病; 中药单体; 中药治疗
Keywords:
Non-alcoholic fatty liver disease; Chinese medicine monomer; Chinese medicine treatment
分类号:
R284
DOI:
10.3969/j.issn.1006-1959.2018.21.008
文献标志码:
A
摘要:
非酒精性脂肪性肝病是目前最常见的慢性肝病之一，尚缺乏特效的治疗药物。近年来研究结果表明中药单体可通过多靶点、多通路治疗非酒精性脂肪性肝病，具有潜在优势。现对中药单体治疗NAFLD的研究进展作一综述。
Abstract:
Non-alcoholic fatty liver disease is one of the most common chronic liver diseases, and there is still no specific treatment for it. In recent years, the results show that Chinese medicine monomer can have non-alcoholic fatty liver disease through multiple targets and multiple pathways, which has potential advantages. The research progress of traditional Chinese medicine monomer treatment of NAFLD is reviewed.

参考文献/References:

[1]Petta S,Camma C,Cabibi,et al.Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2011,34(7):757-766. [2]Sertoglu E,Ercin CN,Celebi G,et al.The relationship of serum uric acid with non-alcoholic fatty liver disease[J].Clin Biochem,2014,47(6):383-388. [3]任习芳,艾耀伟,潘志红,等.非酒精性脂肪肝血尿酸水平与胰岛素抵抗的相关性[J].世界华人消化杂志,2012,20(25):2410-2413. [4]黄立飞.浅谈中医对非酒精性脂肪肝病因病机的认识及辨证论治[J].中医临床研究,2017,9(9):88-90. [5]林琳.上海社区人群血尿酸水平与非酒精性脂肪肝的相关性研究[C]//中华医学会、中华医学会内分泌学分会.中华医学会第十二次全国内分泌学学术会议论文汇编.中华医学会、中华医学会内分泌学分会，2013. [6]Pan YT,Xu FY,Yu XZ,et al.Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease[J].Chin J Chin Mater Med, 2017,42(6):1109-1112. [7]罗先钦,黄崇刚,伍小波,等.山楂总黄酮对复合因素致大鼠脂肪肝模型脂质代谢与低密度脂蛋白受体表达的影响[J].中草药,2011,42(7):1367-1373. [8]Li XD,Chen ZY,Yu JS,et al.Effect of total flavones of hawthorn leafonon expression of COX-2/Nrf2 in liver of rats with nonalcoholic steatohepatitis[J].Chin J Chin Mater Med,2016,41(4):711-715. [9]Li Z,Xu J,Zheng P,et al.Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway[J].Int J Clin Exp Med,2015,8(10):17295-17307. [10]林秋香,周冬生,白纪红,等.银杏黄酮对非酒精性脂肪肝病小鼠肝脏NF-κBp65和TNF-α的影响[J].重庆医学,2014,43(26):3409-3411. [11]白纪红,梁志清,赵日红,等.银杏黄酮对非酒精性脂肪肝小鼠肝脏Toll样受体-4和核因子-κB表达的影响[J].实用医学杂志,2015,31(7):1091-1095. [12]薛城敬,苏言辉，王亚洲，等.桑叶黄酮对2型糖尿病并发单纯性脂肪肝大鼠肝组织PPARγ的影响[J]. 中国现代医生,2014,52(26):1-4. [13]郑琳颖,潘竞锵,杨以琳,等.白芍总苷下调果糖-高脂诱导大鼠非酒精性脂肪性肝病ERK1/2,TLR4和TRL9蛋白表达的作用[J].中国药学杂志,2014,49(24):2168-2172. [14]黄桢,魏毅,王卓,等.白芍总苷对NAFLD大鼠炎症通路中TLR4和JNK蛋白表达的影响[J].湖南师范大学学报(医学版),2018,15(2):23-27. [15]Ma Z,Chu L,Liu H,et al.Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-κB pathway[J].Int Immunopharmacol,2016(38):377-384. [16]阮丹,雷婧.绞股蓝总皂苷对非酒精性脂肪肝大鼠Treg/Th17免疫功能的影响[J].中国现代应用药学，2017,34(12):1683-1688. [17]He Q,Li JK,Li F,et al.Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats[J].World J Gastroenterol,2015,21(7):2058-2566. [18]Li H,Ying H,Hu A,et al.Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation[J].Biol Pharm Bull,2017,40(5):650-657. [19]李国辉,周海虹,赵正晓,等.栀子苷对非酒精性脂肪性肝病金黄地鼠脂质代谢及炎症损伤的影响[J].中国中医基础医学杂志,2015,21(5):524-525. [20]Liang HQ,Lin MT,Zhao X,et al.Mechanism of geniposide in improving free fatty acid metabolism in rats with non-alcoholic fatty liver disease[J].Chin J Chin Mater Med,2016,41(3):470-475. [21]陆奇群,张曦.白藜芦醇通过诱导自噬改善高脂饮食小鼠非酒精性脂肪肝[J].浙江中西医结合杂志,2018,28(1):13-15. [22]杨庆宇,郜娜.白藜芦醇通过miRNA-122调节神经酰胺水平而治疗非酒精性脂肪肝[J].中国病理生理杂志,2017,33(8):1506-1513. [23]Andrade JM,Paraíso AF,de Oliveira MV,et al.Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation[J].Nutrition,2014,30(7-8):915-919. [24]Kessoku T,Imajo K,Honda Y,et al.Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis[J].Sci Rep,2016(6):22251. [25]Yang QH,Hu SP,Zhang YP,et al.Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats[J].Chin J Integr Med,2011,17(3):205-211. [26]Xing LJ,Zhang L,Liu T,et al.Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver[J].Eur J Pharmacol,2011, 668(3):467-471. [27]Yang J,Ma X J,Li L,et al.Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/-mice [J].Exp Ther Med,2017, 14(5):4134-4140. [28]Li X,Xu Z,Wang S,et al.Emodin ameliorates hepatic steatosis through endoplasmic reticulum-stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats[J].Hepatol Res,2016,46(3):E105-E117. [29]Wang S,Li X,Guo H,et al.Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway[J].Hepatol Res,2016,47(7):683-701. [30]Ding C,Zhao Y,Shi X,et al.New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats[J].Sci Rep,2016 (6):28734. [31]Zeng W,Shan W,Gao L,et al.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease[J].Sci Rep,2015(5):16013.

相似文献/References:

[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
　LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(21):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
　FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Journal of Medical Information,2018,31(21):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[3]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
　ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Journal of Medical Information,2018,31(21):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[4]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
　HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in A Certain Area of Tianjin[J].Journal of Medical Information,2019,32(21):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[5]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
　YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(21):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[6]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病 中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
　WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(21):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[7]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
　LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Journal of Medical Information,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[8]钟小丽,龚先琼.基于JAK2/STAT3信号通路探讨中药单体治疗肝癌的研究[J].医学信息,2020,33(01):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
　ZHONG Xiao-li,GONG Xian-qiong.Study on the Treatment of Liver Cancer with Traditional Chinese Medicine Monomer Based on JAK2/STAT3 Signaling Pathway[J].Journal of Medical Information,2020,33(21):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
[9]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[10]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
　CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Journal of Medical Information,2020,33(21):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]

更新日期/Last Update: 2018-11-20